Bibliography
- Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96
- Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain 2013;14:1
- Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain 2011;12:593-601
- WHO. Lifting the burden. Atlas of headache disorders and resources in the world. Springer Verlag; Milan: 2011
- Martelletti P, Birbeck GL, Katsarava Z, et al. The Global Burden of Disease survey 2010, lifting the burden and thinking outside-the-box on headache disorders. J Headache Pain 2013;14:13
- Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 2012;13:361-78
- Farinelli I, De Filippis S, Coloprisco G, et al. Future drugs for migraine. Intern Emerg Med 2009;4:367-73
- Lionetto L, Negro A, Palmisani S, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 2012;17:393-406
- Negro A, Lionetto L, D’Alonzo L, et al. Pharmacokinetic evaluation of almotriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol 2013;9:637-44
- Lionetto L, Negro A, Casolla B, et al. Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice. Expert Opin Pharmacother 2012;13:2369-80
- Lionetto L, Casolla B, Mastropietri F, et al. Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol 2012;8:1043-50
- Negro A, Lionetto L, Casolla B, et al. Pharmacokinetic evaluation of frovatriptan. Expert Opin Drug Metab Toxicol 2011;7:1449-58
- Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259-87
- Dodick D, Lipton RB, Martin V, et al. Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004;44(5):414-25
- Cevoli S, D’Amico D, Martelletti P, et al. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia 2009;29:1285-93
- Chiossi L, Negro A, Capi M, et al. Sodium channel antagonists for the treatment of migraine. Expert Opin Pharmacother 2014;15:1697-706
- Martelletti P. Dispute settlement understanding on the use of Botox in chronic migraine. J Headache Pain 2011;12:1-2
- Tfelt-Hansen PC, Olesen J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain 2012;13:271-5